Archives

Long-Acting Drug Delivery Systems for ART Optimization in Children Living with HIV-1 II (LADDS II) (R61/R33 Clinical Trial Not Allowed)

Grant Source: 
NIH/NIAID

The purpose of this Notice of Funding Opportunity (NOFO) is to accelerate the development of safe and effective long-acting drug delivery systems for improved, simplified treatment of HIV-1 in children. This NOFO invites applicants engaged in the development of existing long-acting platforms at early stages of development stages to perform specific preclinical activities that enable product optimization and accelerated translation to HIV-infected children. Collaborative research partnerships with industry are required.

MATRIX Prevention Challenges RFA

Grant Source: 
USAID

The MATRIX Prevention Challenges RFA is now open. The objective of this funding opportunity is to support the development of solutions to specific challenges facing the field of HIV prevention. Investigators and institutions from Kenya, South Africa, Zimbabwe, United States (US), European Union (EU), or United Kingdom (UK), are invited to apply to this request for applications (RFA) sponsored by MATRIX: A USAID Project to Advance the Research and Development of Innovative HIV Prevention Products for Women. 

Increasing Uptake of Long-Acting Injectable Antiretrovirals Among People with HIV

Grant Source: 
HRSA

This notice announces the opportunity to apply for funding under the Increasing Uptake of Long-Acting Injectable Antiretrovirals Among People with HIV cooperative agreement Increasing viral suppression and client retention in care are critical components of meeting the goals of the National HIV/AIDS Strategy (2022-2025) and ending the HIV epidemic. In order to reach these goals, it is imperative for HIV care communities to address health care inequities. With the advent of FDA-approved long-acting injectable (LAI) antiretroviral (ARV) medication formulations, initiatives that promote, facilitate, and evaluate the uptake and ongoing utilization of LAI ARV medication may improve clinical outcomes for people with HIV, especially for minority populations who continue to face disparate health care inequities and stigma. This project is designed to develop protocols, implement them and modify as needed, to increase uptake of LAI ARV medications among people of color with HIV, since LAI ARV medications may offer benefits in addressing health inequities and achieving viral suppression.

Health Topics: 
HIV

Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01 Clinical Trial Not Allowed)

Grant Source: 
NIH/NIAID

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the high-risk research needed to develop new and innovative sustained release antiviral strategies for treatment of HIV disease or the prevention of HIV transmission and acquisition. Adherence to dosing regimens is a shared critical issue for both HIV treatment and prevention.

Health Topics: 
HIV
LA/ER Injectable Therapy

Advancing Sustained/Extended Release for HIV Prevention (A-SER)

Grant Source: 
NIH/NIAID

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the development of new and innovative sustained/extended release (SER) drug delivery systems (DDS) that can achieve extended durations (months to years) and provide systemic protection from all routes of HIV infection/transmission in at-risk individuals.

Application Deadline: December 4, 2019, by 5:00 PM local time of applicant organization

Health Topics: 
HIV
LA/ER Implantable Therapy
LA/ER Injectable Therapy
LA/ER Transdermal Drug Delivery

Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed)

Grant Source: 
NIH/NIAID

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate development of safe and effective long-acting drug delivery systems (LA-DDS) for improved, simplified treatment of HIV-1 in children. This FOA invites applicants engaged in the development of existing LA-DDS platforms at early product development stages to perform specific preclinical activities that enable product optimization and accelerated translation to HIV-1 infected children. Collaborative research partnerships with industry are required.

Application Deadline: March 13, 2019 - 5:00 PM local time of applicant

Health Topics: 
HIV
Pediatric Formulations

Emerging Technologies for New Solutions in Global Health Priority Areas (Round 23)

Grant Source: 
Gates

​THE OPPORTUNITY
A set of rapidly-evolving technologies is changing the world and expanding the realm of the possible. These emerging technologies include – but are not limited to – artificial intelligence, materials science, wearable sensors, synthetic biology, nanotechnology, microscopy, augmented and virtual reality, geospatial mapping, robotics, and DNA sequencing. 
DEADLINE: 10 APR 2019 - 11:30AM PDT

Health Topics: 
Tuberculosis

Accelerating impact of long-acting technologies in low- and middle-income countries (LMICs)

Grant Source: 
UNITAID

Safe and efficacious medicines are available for the prevention and treatment of major diseases, but their effectiveness can be compromised by poor treatment completion. Lack of adherence can worsen clinical outcomes, leading to increased mortality, persistent transmission and increased drug resistance in the case of antimicrobials and antivirals. Analyses of treatment and prevention of HIV, malaria, and TB within public health programs show wide disparities in rates of completion, especially among specific populations and regions.

Application Deadline: 23 April 2019

Health Topics: 
HIV
LA/ER Implantable Therapy
LA/ER Injectable Therapy
LA/ER Oral Therapy
Tuberculosis

Pages